High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials

Precision Medicine Approach in a Large Market: Licaminlimab is positioned as a potential first-in-class precision medicine for an estimated 1.5+ million patients in the U.S. with moderate-to-severe TNFR1-mediated dry eye disease (DED)1-4, addressing a critical unmet need in a historically heterogeneous indication.

Key Milestone on Track: Topline data from this first-ever genotype-guided registrational trial in DED are anticipated around year-end 2026

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.